Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy

Charcot Joint of Foot Clinical Trial

Official title:

Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03174366
• Other study ID #: 20159178
• Status: Completed
• Phase: Phase 3
• Start date: May 16, 2017
• Est. completion date: March 6, 2019

Study information

• Verified date: October 2019
• Source: Western University of Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences frequently lead to below-knee amputation of the affected limb.

Currently treatment options are limited, and no pharmaceutical treatment has been efficacious in the medical literature. The purpose of this pilot study is to investigate the potential of the medication denosumab for acute stage Charcot neuroarthropathy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: March 6, 2019
• Est. primary completion date: June 18, 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• Men or women > 30 years old

• Subject is able and willing to comply with study procedures, and is able to give signed and dated consent

• Subject meets criteria for diagnosis of Diabetes Mellitus Type 1 or 2, active Charcot neuroarthropathy, and peripheral neuropathy

• Subjects with serum calcium or albumin-adjusted serum calcium =2.0 mmol/L (8.0mg/dL)

Exclusion Criteria:

• Unable to provide signed and dated consent.

• Charcot neuroarthropathy of the ipsilateral lower extremity, diagnosed over 1 month prior.

• Prior foot or ankle surgery of the ipsilateral lower extremity.

• Prior amputation at any level of either lower extremity.

• Prior foot or ankle fracture of the ipsilateral lower extremity unrelated to the current acute CN episode.

• Currently has any of the following:

1. Infection

2. Foot ulceration

3. Hypocalcemia

4. Creatinine clearance less than 30 mL/min or on dialysis

5. Pre-existing disturbance of mineral metabolism (e.g., hypoparathyroidism unstable on therapy, thyroid or parathyroid surgery, vitamin D deficiency, malabsorption syndromes, excision of small intestine, history of diseases affecting bone metabolism) that has not been effectively corrected or treated.

• Have undergone revascularization procedures of the lower extremities.

• Female subjects who are pregnant or planning to breastfeed should not participate in this study.

• Determined to have poor oral hygiene after dental screening or are at increased risk for developing osteonecrosis of the jaw.

• History of osteonecrosis of the jaw.

• History of tooth extraction or other dental surgery within the prior 6 months.

• Invasive dental work planned in the next 2 years.

• Have a known hypersensitivity to Prolia.

• Known use of a bone active medication within the 6 months prior to enrollment.

• Liver disease, defined as AST > 2.0x ULN, ALT > 2.0x ULN, TBL > 1.5x ULN.

• Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma)

Related Conditions & MeSH terms

• Arthropathy, Neurogenic
• Charcot Joint of Foot

Intervention

Drug:
• Denosumab
Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.

Locations

Country	Name	City	State
United States	Western University of Health Sciences	Pomona	California

Sponsors (1)

Lead Sponsor	Collaborator
Western University of Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	1 year
Secondary	Change in Skin Temperature Difference in Degrees Celsius Between the Affected and Non-affected Limb at 6 Months.	Change in skin temperature difference in degrees Celsius between the affected and non-affected limb at 6 months.	6 months